Takeda Pharmaceutical (NYSE:TAK) Releases Earnings Results, Beats Estimates By $0.08 EPS

by · The Markets Daily

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) posted its quarterly earnings results on Thursday. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08, Zacks reports. Takeda Pharmaceutical had a return on equity of 10.00% and a net margin of 6.49%. Takeda Pharmaceutical updated its FY 2024 guidance to 3.330-3.330 EPS.

Takeda Pharmaceutical Price Performance

NYSE TAK opened at $13.41 on Friday. The company has a 50 day simple moving average of $13.31 and a 200-day simple moving average of $13.88. Takeda Pharmaceutical has a 52-week low of $12.57 and a 52-week high of $15.08. The firm has a market capitalization of $42.65 billion, a price-to-earnings ratio of 23.11, a price-to-earnings-growth ratio of 0.25 and a beta of 0.51. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77.

Takeda Pharmaceutical Company Profile

(Get Free Report)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

See Also